Opinion/decision on a Paediatric investigation plan (PIP): Ebglyss, Lebrikizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0382/2024

EMEA-002905-PIP01-20-M01

EMEA-003133-PIP01-21-M01

EMEA-003174-PIP01-21-M02

EMEA-003426-PIP01-23-M02

List of European Union reference dates (EURD) and frequency of submission of periodic safety update reports (PSURs)

Human medicines European public assessment report (EPAR): Aqumeldi, enalapril maleate, Date of authorisation: 15/11/2023, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Idacio, adalimumab, Date of authorisation: 02/04/2019, Revision: 14, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Nucala, Mepolizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immune system disorders, PIP number: P/0367/2024

Scientific recommendations on classification of advanced therapy medicinal products